Corient Private Wealth LP Buys 254,124 Shares of ADMA Biologics Inc $ADMA

Key Points

• Corient Private Wealth LP increased its ADMA Biologics stake by 398.7% in the second quarter, purchasing 254,124 additional shares for a total of 317,861 shares valued at approximately $2.66 million.
• ADMA has a “Moderate Buy” consensus rating from analysts, with an average price target of $18.67 versus the stock’s recent price of $9.51.
• ADMA’s latest quarterly results met earnings expectations at $0.16 per share, while revenue reached $124.39 million, up 2% year over year but slightly below analyst estimates.

Corient Private Wealth LP boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 398.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 317,861 shares of the biotechnology company's stock after purchasing an additional 254,124 shares during the quarter. Corient Private Wealth LP owned 0.14% of ADMA Biologics worth $2,660,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of ADMA. Western Wealth Management LLC bought a new position in shares of ADMA Biologics during the 1st quarter worth about $31,000. Quantbot Technologies LP bought a new stake in shares of ADMA Biologics in the second quarter valued at about $51,000. Larson Financial Group LLC increased its stake in ADMA Biologics by 745.1% during the fourth quarter. Larson Financial Group LLC now owns 3,262 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 2,876 shares during the period. Nykredit A S acquired a new stake in shares of ADMA Biologics during the 2nd quarter worth approximately $59,000. Finally, Allworth Financial LP acquired a new position in shares of ADMA Biologics in the second quarter valued at $68,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ADMA has been the topic of several recent research reports. Zacks Research upgraded shares of ADMA Biologics from a "strong sell" rating to a "hold" rating in a research report on Wednesday, September 2nd. Mizuho cut their target price on ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Wednesday, July 15th. Weiss Ratings reiterated a "hold (c)" rating on shares of ADMA Biologics in a research report on Monday, September 14th. Finally, Raymond James Financial initiated coverage on ADMA Biologics in a report on Wednesday, June 10th. They set an "outperform" rating and a $21.00 price objective for the company. Three research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, ADMA Biologics currently has a consensus rating of "Moderate Buy" and an average price target of $18.67.

ADMA Biologics Trading Up 4.4%

ADMA stock opened at $9.51 on Tuesday. The business has a fifty day moving average price of $9.22 and a 200 day moving average price of $9.75. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. ADMA Biologics Inc has a fifty-two week low of $7.21 and a fifty-two week high of $20.46. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 13.59 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The company had revenue of $124.39 million for the quarter, compared to analysts' expectations of $125.34 million. During the same quarter in the prior year, the business earned $0.14 earnings per share. The business's revenue for the quarter was up 2.0% on a year-over-year basis. Analysts expect that ADMA Biologics Inc will post 0.78 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company's activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA's marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.